Real‑world evidence of advanced non‑small cell lung carcinoma treated with an immune checkpoint inhibitor plus chemotherapy

Xu,Zihan; Zhang,Huien; Ma,Guikai; Meng,Wenjuan; Du,Junliang; Wu,Xin; Yang,Baohong; Wang,Ningning; Ding,Yanhong; Zhang,Qingyun; Li,Na; Zhang,Xuede; Yu,Guohua; Liu,Shuzhen; Li,Zhenhua

doi:10.3892/ol.2024.14538

Real‑world evidence of advanced non‑small cell lung carcinoma treated with an immune checkpoint inhibitor plus chemotherapy

Authors:
- Zihan Xu
- Huien Zhang
- Guikai Ma
- Wenjuan Meng
- Junliang Du
- Xin Wu
- Baohong Yang
- Ningning Wang
- Yanhong Ding
- Qingyun Zhang
- Na Li
- Xuede Zhang
- Guohua Yu
- Shuzhen Liu
- Zhenhua Li
View Affiliations

Affiliations: Department of Oncology, The First Affiliated Hospital of Shandong Second Medical University, Weifang, Shandong 261000, P.R. China
Published online on: June 27, 2024 https://doi.org/10.3892/ol.2024.14538
Article Number: 405
Copyright: © Xu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Immunotherapy is an effective treatment strategy for patients with advanced non‑small cell lung cancer (NSCLC). Although clinical trials on immunotherapy have provided promising results, real‑world research in clinical practice is needed to assess the effectiveness and safety of immunotherapy. The present study aimed to characterize real‑world outcomes in patients with advanced NSCLC treated with immune checkpoint inhibitor (ICI)‑based regimens. The medical records of patients with advanced NSCLC, who were treated with programmed cell death protein‑1 (PD‑1)/programmed cell death 1 ligand 1 (PD‑L1) inhibitors, were reviewed for data collection. The primary objectives were to evaluate progression‑free survival (PFS) and overall survival (OS). Therefore, multiple Cox regression models were used to investigate the predictive factors for survival outcomes. Furthermore, survival curves for PFS and OS were created using Kaplan‑Meier estimates and compared using the log‑rank test. The present study included a total of 133 patients with advanced NSCLC who received therapy with ICIs between January 1, 2019 and December 31, 2022. The final follow‑up date was August 24, 2023. The median PFS and OS times were 9.8 and 27.2 months, respectively. Univariate Cox regression analysis demonstrated that sex, clinical stage, PD‑L1 status, previous systemic therapy, and brain and liver metastases were associated with PFS, while Eastern Cooperative Oncology Group (ECOG) status, clinical stage, PD‑L1 status and brain metastasis were associated with OS. Furthermore, multivariate Cox regression analysis demonstrated that a PD‑L1 tumor proportion score (TPS) of ≥50% was an indicator of favorable PFS and OS. An ECOG performance status score of ≥1 was also associated with poor OS but not with PFS. Furthermore, brain metastasis was an indicator for poor PFS and OS, while liver metastasis was only associated with a poor PFS. Finally, the results of the present study demonstrated that PD‑L1 status was an independent predictor for PFS and OS in patients with advanced NSCLC, especially adenocarcinoma, who were treated with ICIs plus chemotherapy. The results also suggested that patients with a PD‑L1 TPS of ≥50% could benefit when the aforementioned regimens were administrated as a first‑line or later‑line therapy.

View Figures

View References

1	Li Y, Yan B and He S: Advances and challenges in the treatment of lung cancer. Biomed Pharmacother. 169:1158912023. View Article : Google Scholar : PubMed/NCBI
2	Gao S, Li N, Wang S, Zhang F, Wei W, Li N, Bi N, Wang Z and He J: Lung Cancer in People's Republic of China. J Thorac Oncol. 15:1567–1576. 2020. View Article : Google Scholar : PubMed/NCBI
3	Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A and Bray F: Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 71:209–249. 2021. View Article : Google Scholar : PubMed/NCBI
4	Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, Zhu J and Johnson DH; Eastern Cooperative Oncology Group, : Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med. 346:92–98. 2002. View Article : Google Scholar : PubMed/NCBI
5	Cufer T, Ovcaricek T and O'Brien ME: Systemic therapy of advanced non-small cell lung cancer: Major-developments of the last 5-years. Eur J Cancer. 49:1216–1225. 2013. View Article : Google Scholar : PubMed/NCBI
6	Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, Lilenbaum R and Johnson DH: Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 355:2542–2550. 2006. View Article : Google Scholar : PubMed/NCBI
7	Kader YA, Le Chevalier T, El-Nahas T and Sakr A: Comparative study analyzing survival and safety of bevacizumab/carboplatin/paclitaxel and cisplatin/pemetrexed in chemotherapy-naive patients with advanced non-squamous bronchogenic carcinoma not harboring EGFR mutation. Onco Targets Ther. 6:803–809. 2013.PubMed/NCBI
8	Chen P, Liu Y, Wen Y and Zhou C: Non-small cell lung cancer in China. Cancer Commun (Lond). 42:937–970. 2022. View Article : Google Scholar : PubMed/NCBI
9	Kaur J, Elms J, Munn AL, Good D and Wei MQ: Immunotherapy for non-small cell lung cancer (NSCLC), as a stand-alone and in combination therapy. Crit Rev Oncol Hematol. 164:1034172021. View Article : Google Scholar : PubMed/NCBI
10	Kim H and Chung JH: PD-L1 testing in non-small cell lung cancer: Past, present, and future. J Pathol Transl Med. 53:199–206. 2019. View Article : Google Scholar : PubMed/NCBI
11	Ramagopal UA, Liu W, Garrett-Thomson SC, Bonanno JB, Yan Q, Srinivasan M, Wong SC, Bell A, Mankikar S, Rangan VS, et al: Structural basis for cancer immunotherapy by the first-in-class checkpoint inhibitor ipilimumab. Proc Natl Acad Sci USA. 114:E4223–E4232. 2017. View Article : Google Scholar : PubMed/NCBI
12	Reck M, Rodriguez-Abreu D, Robinson AG, Hui R, Csoszi T, Fulop A, Gottfried M, Peled N, Tafreshi A, Cuffe S, et al: Updated Analysis of KEYNOTE-024: Pembrolizumab versus platinum-based chemotherapy for advanced non-small-cell lung cancer with PD-L1 tumor proportion score of 50% or Greater. J Clin Oncol. 37:537–546. 2019. View Article : Google Scholar : PubMed/NCBI
13	Mok TSK, Wu YL, Kudaba I, Kowalski DM, Cho BC, Turna HZ, Castro GJ Jr, Srimuninnimit V, Laktionov KK, Bondarenko I, et al: Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): A randomised, open-label, controlled, phase 3 trial. Lancet. 393:1819–1830. 2019. View Article : Google Scholar : PubMed/NCBI
14	Jassem J, de Marinis F, Giaccone G, Vergnenegre A, Barrios CH, Morise M, Felip E, Oprean C, Kim YC, Andric Z, et al: Updated Overall Survival Analysis From IMpower110: Atezolizumab versus platinum-based chemotherapy in treatment-naive programmed death-ligand 1-Selected NSCLC. J Thorac Oncol. 16:1872–1882. 2021. View Article : Google Scholar : PubMed/NCBI
15	Yang Y, Sun J, Wang Z, Fang J, Yu Q, Han B, Cang S, Chen G, Mei X, Yang Z, et al: Updated overall survival data and predictive biomarkers of sintilimab plus pemetrexed and platinum as first-line treatment for locally advanced or metastatic nonsquamous NSCLC in the Phase 3 ORIENT-11 Study. J Thorac Oncol. 16:2109–2120. 2021. View Article : Google Scholar : PubMed/NCBI
16	Rittmeyer A, Barlesi F, Waterkamp D, Park K, Ciardiello F, von Pawel J, Gadgeel SM, Hida T, Kowalski DM, Dols MC, et al: Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): A phase 3, open-label, multicentre randomised controlled trial. Lancet. 389:255–265. 2017. View Article : Google Scholar : PubMed/NCBI
17	Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, et al: New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247. 2009. View Article : Google Scholar : PubMed/NCBI
18	Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, Mcfadden ET and Carbone PP: Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 5:649–655. 1982. View Article : Google Scholar : PubMed/NCBI
19	Hwang JK, Page BJ, Flynn D, Passmore L, Mccau E, Brady J, Yang IA, Marshall H, Windsor M, Bowman RV, et al: Validation of the Eighth Edition TNM Lung Cancer Staging System. J Thorac Oncol. 15:649–654. 2020. View Article : Google Scholar : PubMed/NCBI
20	Tsao MS, Kerr KM, Kockx M, Beasley MB, Borczuk AC, Botling J, Bubendorf L, Chirieac L, Chen G, Chou TY, et al: PD-L1 Immunohistochemistry comparability study in real-life clinical samples: Results of blueprint phase 2 project. J Thorac Oncol. 13:1302–1311. 2018. View Article : Google Scholar : PubMed/NCBI
21	Gadgeel S, Rodriguez-Abreu D, Speranza G, Esteban E, Felip E, Domine M, Hui R, Hochmair MJ, Clingan P, Powell SF, et al: Updated Analysis From KEYNOTE-189: Pembrolizumab or placebo plus pemetrexed and platinum for previously untreated metastatic nonsquamous non-small-cell lung cancer. J Clin Oncol. 38:1505–1517. 2020. View Article : Google Scholar : PubMed/NCBI
22	Wu YL, Lu S, Cheng Y, Zhou C, Wang J, Mok T, Zhang L, Tu HY, Wu L, Feng J, et al: Nivolumab versus docetaxel in a predominantly chinese patient population with previously treated advanced NSCLC: CheckMate 078 randomized phase III clinical trial. J Thorac Oncol. 14:867–875. 2019. View Article : Google Scholar : PubMed/NCBI
23	Zhou C, Chen G, Huang Y, Zhou J, Lin L, Feng J, Wang Z, Shu Y, Shi J, Hu Y, et al: Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): A randomised, open-label, multicentre, phase 3 trial. Lancet Respir Med. 9:305–314. 2021. View Article : Google Scholar : PubMed/NCBI
24	Lu S, Wang J, Yu Y, Yu X, Hu Y, Ai X, Ma Z, Li X, Zhuang W, Liu Y, et al: Tislelizumab plus chemotherapy as first-line treatment for locally advanced or metastatic nonsquamous NSCLC (RATIONALE 304): A Randomized phase 3 trial. J Thorac Oncol. 16:1512–1522. 2021. View Article : Google Scholar : PubMed/NCBI
25	Negrao MV, Skoulidis F, Montesion M, Schulze K, Bara I, Shen V, Xu H, Hu S, Sui D, Elamin YY, et al: Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancer. J Immunother Cancer. 9:e0028912021. View Article : Google Scholar : PubMed/NCBI
26	Horn L, Spigel DR, Vokes EE, Holgado E, Ready N, Steins M, Poddubskaya E, Borghaei H, Felip E, Paz-Ares L, et al: Nivolumab versus docetaxel in previously treated patients with advanced non-small-cell lung cancer: Two-Year outcomes from two Randomized, open-label, phase III trials (CheckMate 017 and CheckMate 057). J Clin Oncol. 35:3924–3933. 2017. View Article : Google Scholar : PubMed/NCBI
27	Borghaei H, Gettinger S, Vokes EE, Chow LQM, Burgio MA, de Castro Carpeno J, Pluzanski A, Arrieta O, Frontera OA, Chiari R, et al: Five-Year outcomes from the Randomized, phase III Trials CheckMate 017 and 057: Nivolumab versus docetaxel in previously treated non–small-cell lung cancer. J Clin Oncol. 39:723–733. 2021. View Article : Google Scholar : PubMed/NCBI
28	Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, Chow LQ, Vokes EE, Felip E, Holgado E, et al: Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med. 373:1627–1639. 2015. View Article : Google Scholar : PubMed/NCBI
29	Gandhi L, Rodriguez-Abreu D, Gadgeel S, Esteban E, Felip E, De Angelis F, Domine M, Clingan P, Hochmair MJ, Powell SF, et al: Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N Engl J Med. 378:2078–2092. 2018. View Article : Google Scholar : PubMed/NCBI
30	West H, Mccleod M, Hussein M, Morabito A, Rittmeyer A, Conter HJ, Kopp HG, Daniel D, Mccune S, Mekhail T, et al: Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): A multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 20:924–937. 2019. View Article : Google Scholar : PubMed/NCBI
31	Waterhouse D, Lam J, Betts KA, Yin L, Gao S, Yuan Y, Hartman J, Rao S, Lubinga S and Stenehjem D: Real-world outcomes of immunotherapy-based regimens in first-line advanced non-small cell lung cancer. Lung Cancer. 156:41–49. 2021. View Article : Google Scholar : PubMed/NCBI
32	Nishio M, Barlesi F, West H, Ball S, Bordoni R, Cobo M, Longeras PD, Goldschmidt J Jr, Novello S, Orlandi F, et al: Atezolizumab plus chemotherapy for first-line treatment of nonsquamous NSCLC: Results from the Randomized phase 3 IMpower132 Trial. J Thorac Oncol. 16:653–664. 2021. View Article : Google Scholar : PubMed/NCBI
33	Tournoy KG, Thomeer M, Germonpre P, Derijcke S, De Pauw R, Galdermans D, Govaert K, Govaerts E, Schildermans R, Declercq I, et al: Does nivolumab for progressed metastatic lung cancer fulfill its promises? An efficacy and safety analysis in 20 general hospitals. Lung Cancer. 115:49–55. 2018. View Article : Google Scholar : PubMed/NCBI
34	Funazo T, Nomizo T and Kim YH: Liver metastasis is associated with poor progression-free survival in patients with non-small cell lung cancer treated with nivolumab. J Thorac Oncol. 12:e140–e141. 2017. View Article : Google Scholar : PubMed/NCBI
35	Ikeuchi N, Igata F, Kinoshita E, Kawabata T, Tan I, Osaki Y, Otsuka R, On R, Ikeda T, Nakao A, et al: Real-world efficacy and safety of atezolizumab plus bevacizumab, paclitaxel and carboplatin for first-line treatment of Japanese patients with metastatic non-squamous non-small cell lung cancer. Anticancer Res. 43:713–724. 2023. View Article : Google Scholar : PubMed/NCBI
36	Zheng L, Xiong A, Wang S, Xu J, Shen Y, Zhong R, Lu J, Chu T, Zhang W, Li Y, et al: Decreased monocyte-to-lymphocyte ratio was associated with satisfied outcomes of first-line PD-1 inhibitors plus chemotherapy in stage IIIB-IV non-small cell lung cancer. Front Immunol. 14:10943782023. View Article : Google Scholar : PubMed/NCBI
37	Gu X, Shi Z, Shao L, Zhang Y, Zhang Y, Song Z, Wang W and Lou G: Efficacy and safety of maintenance immune checkpoint inhibitors with or without pemetrexed in advanced non-squamous non-small cell lung cancer: A retrospective study. BMC Cancer. 22:5762022. View Article : Google Scholar : PubMed/NCBI
38	Perol M, Felip E, Dafni U, Polito L, Pal N, Tsourti Z, Ton TGN, Merritt D, Morris S, Stahel R and Peters S: Effectiveness of PD-(L)1 inhibitors alone or in combination with platinum-doublet chemotherapy in first-line (1L) non-squamous non-small-cell lung cancer (Nsq-NSCLC) with PD-L1-high expression using real-world data. Ann Oncol. 33:511–521. 2022. View Article : Google Scholar : PubMed/NCBI